Skip Navigation


Glycobiology Advance Access originally published online on June 1, 2009
Glycobiology 2009 19(8):813-815; doi:10.1093/glycob/cwp069
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/8/813    most recent
cwp069v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by David-Raoudi, M
Right arrow Articles by Pujol, J P
PubMed
Right arrow PubMed Citation
Right arrow Articles by David-Raoudi, M
Right arrow Articles by Pujol, J P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

For intra-articular delivery of chondroitin sulfate

M David-Raoudi2, R Mendichi3 and J P Pujol1,2

2 Laboratory of Connective Tissue Biochemistry, Faculty of Medicine, University of Caen, 14032 Caen Cedex, France
3 Istituto per lo Studio delle Macromolecole Istituto per lo Studio delle Macromolecole Via E. Basini 15, I-20133 Milano, Italy

1 To whom correspondence should be addressed: Tel: +33-2-31-06-82-18; Fax: +33-2-31-06-82-28; e-mail: jean-pierre.pujol@unicaen.fr

The first 10% of the full text of this article appears below.

So far, there is no efficient treatment that could stop the pathological process of osteoarthritis (OA), and the management of the disease is mainly based on the alleviation of clinical symptoms by nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics compounds. However, some natural products have been proposed as symptomatic treatments, and named symptomatic slow acting disease modifying drugs (SYSADOA). They include glucosamine sulfate (GS), chondroitin sulfate (CS), hyaluronan (intra-articular injection), diacerhein, and avocado/soybean unsaponifiable extracts. GS and CS are sold as neutraceuticals over-the-counter in the United States but they are clinically used as anti-arthrosic drugs in some European countries. However, their clinical efficacy has never been clearly demonstrated and the recent large-scale multicenter trial Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) showed . . . [Full Text of this Article]

Funding

Conflict of interest statement


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?